Skip to content

Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies

Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-dose Cyclophosphamide Versus Plerixafor

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02997813
Acronym
MOZOBIL
Enrollment
112
Registered
2016-12-20
Start date
2015-06-30
Completion date
2016-12-31
Last updated
2016-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Stem Cell Transplant Failure, Multiple Myeloma

Brief summary

This is a retrospective observational cohort database analysis. The study will review retrospectively the records of patients undergoing a first peripheral blood stem cell mobilization for multiple myeloma in the databases from approximately 15 hospitals which are part of the IFM collaborative group. Patient records will be divided into two groups of 50 patients minimum, maximum 100 patients or up to the number of patient records that could be extracted. The first group of patients will have received plerixafor plus G-CSF without the administration of chemotherapy as a mobilization strategy and a second group of patients will have received cyclophosphamide plus G-CSF as a mobilization strategy. All consecutive patients with complete set of data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and plerixafor and all consecutive patients with complete data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and cyclophosphamide will be included. All data that will be analyzed will be extracted from the selected IFM institutions which are located in France.

Interventions

None listed

Sponsors

Intergroupe Francophone du Myelome
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Hematology patients diagnosed with Multiple Myeloma who are candidates for autologous hematopoietic stem cell transplantation (ASCT) upfront. * Age \> 18 years * Undergone prior successful peripheral blood stem cell mobilization with Cyclophosphamid or Plerixafor

Exclusion criteria

* Age \< 18 years; * Primary diagnosis other than Multiple Myeloma

Design outcomes

Primary

MeasureTime frame
Total cost of stem cell mobilization procedure (including remobilisation if applicable)2009-2013

Secondary

MeasureTime frame
Number of visits for administration of mobilizing agents2009-2013
Duration (days) of administration of mobilizing agents2009-2013
Agents used as mobilizing agents2009-2013
Attainment of CD34+ target (yes, no) (min 2.106 cells/kg, ideal >4.106cells/kg)2009-2013
Number of days needed to meet CD34+ target level (min 2.106 cells/kg, ideal >4.106cells/kg)2009-2013

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026